L\u2019IDIBELL ha signat un acord de llic\u00e8ncia amb l\u2019empresa biotecnol\u00f2gica catalana Minoryx d\u2019una patent per al tractament de l\u2019adrenoleucodistr\u00f2fia lligada al cromosoma X, una malaltia rara neurodegenerativa molt greu contra la qual no existeix cap tractament.<\/p>\n
El grup de Malalties Neurometab\u00f2liques, liderat per la investigadora ICREA Aurora Pujol, ha desenvolupat un model animal per estudiar aquesta patologia. Els estudis realitzats amb aquest model han demostrat que el producte patentat, un f\u00e0rmac de reposicionament, pot ser efectiu contra l\u2019adrenoleucodistr\u00f2fia lligada al cromosoma X.<\/p>\n
L\u2019obtenci\u00f3 de la patent, aix\u00ed com la seva llic\u00e8ncia, ha estat gestionada per l\u2019Oficina de Transfer\u00e8ncia de Tecnologia de l\u2019IDIBELL. La llic\u00e8ncia a Minoryx representa una oportunitat no \u00fanicament de fer arribar aquesta invenci\u00f3 al mercat i als pacients, sin\u00f3 tamb\u00e9 d\u2019endegar una col\u00b7laboraci\u00f3 de confian\u00e7a i continuada entre l\u2019empresa i l\u2019IDIBELL en el desenvolupament de noves solucions per a la millora de la qualitat de vida dels malalts amb adrenoleucodistr\u00f2fia.<\/p>\n
Malaltia heredit\u00e0ria<\/strong><\/p>\n L\u2019adrenoleucodistr\u00f2fia lligada a X \u00e9s una malaltia heredit\u00e0ria que destrueix la mielina (la subst\u00e0ncia blanca que recobreix els nervis) del sistema nervi\u00f3s central o del perif\u00e8ric i produeix alteracions hormonals. Els pacients afectats presenten una mutaci\u00f3 gen\u00e8tica que els impedeix degradar correctament els \u00e0cids grassos de cadena molt llarga dintre de les c\u00e8l\u00b7lules. Aix\u00f2 provoca l’acumulaci\u00f3 d’aquest tipus de greix en el plasma i en els teixits, especialment en el cervell i en la gl\u00e0ndula suprarenal, causant danys irreversibles.<\/p>\n La malaltia \u00e9s poc freq\u00fcent i afecta nom\u00e9s individus de sexe mascul\u00ed, tot i que les dones portadores tamb\u00e9 en poden manifestar alguns s\u00edmptomes. La seva incid\u00e8ncia \u00e9s d\u2019un cas per cada 17.000 homes. \u00c9s el tipus m\u00e9s freq\u00fcent de leucodistr\u00f2fia i el principal desordre del peroxisoma (part de la c\u00e8l\u00b7lula encarregada d\u2019eliminar productes t\u00f2xics). La malaltia es va fer famosa l\u2019any 1992 amb la pel\u00b7l\u00edcula \u2018L\u2019oli de la vida\u2019 (Lorenzo\u2019s oil<\/em>), protagonitzada per Nick Nolte i Susan Sarandon.<\/p>\n M\u00e9s estudis<\/strong><\/p>\n El f\u00e0rmac ha obtingut bons resultats en experiments realitzats en animals. Tot i aix\u00ed, encara faran falta m\u00e9s estudis abans que el producte pugui ser aplicat en afectats d\u2019adrenoleucodistr\u00f2fia lligada a X. En aquest sentit, la signatura del contracte de llic\u00e8ncia amb Minoryx suposa un pas important perqu\u00e8 el f\u00e0rmac es pugui emprar amb aquesta finalitat.<\/p>\n Minoryx \u00e9s una empresa biotecnol\u00f3gica situada en la incubadora del TecnoCampus Matar\u00f3-Maresme i dedicada al desenvolupament de solucions terap\u00e8utiques per tractar malalties rares, especialment les que afecten als infants i adolescents. L\u2019aproximaci\u00f3 de Minoryx es basa principalment en dues estrat\u00e8gies complement\u00e0ries: el reposicionament de f\u00e0rmacs i la identificaci\u00f3 d\u2019una nova generaci\u00f3 de f\u00e0rmacs, anomenats xaperones farmacol\u00f2giques, a trav\u00e9s d\u2019una plataforma amb tecnologia pr\u00f2pia.<\/p>\n El desenvolupament de la patent transferida a Minoryx ha estat possible gr\u00e0cies al suport del Ministeri d\u2019Economia i Competitivitat, del Instituto de Salud Carlos III i dels fons europeus per al desenvolupament regional (FEDER). Tamb\u00e9 hi ha col\u00b7laborat la Fundaci\u00f3 ELA que te una petita participaci\u00f3 en al patent.<\/p>\n","protected":false},"excerpt":{"rendered":" L\u2019IDIBELL ha signat un acord de llic\u00e8ncia amb l\u2019empresa biotecnol\u00f2gica catalana Minoryx d\u2019una patent per al tractament de l\u2019adrenoleucodistr\u00f2fia lligada al cromosoma X, una malaltia rara neurodegenerativa molt greu contra la qual no existeix cap tractament. El grup de Malalties Neurometab\u00f2liques, liderat per la investigadora ICREA Aurora Pujol, ha desenvolupat un model animal per estudiar […]<\/p>\n","protected":false},"author":6,"featured_media":20401,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1,380,340,457],"tags":[],"class_list":["post-8559","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar","category-malalties-neurometaboliques","category-neurociencies","category-p-de-neurociencies"],"publishpress_future_action":{"enabled":false,"date":"2024-11-28 16:28:56","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=8559"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8559\/revisions"}],"predecessor-version":[{"id":20402,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8559\/revisions\/20402"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/20401"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=8559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=8559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=8559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}